Dr Michael Hadjihari
drmichaelgp.bsky.social
Dr Michael Hadjihari
@drmichaelgp.bsky.social
Reposted by Dr Michael Hadjihari
www.thelancet.com/journals/lan...
Happy to share 15 year follow-up of our study of rituximab Vs watchful waiting for advanced stage, asymptomatic low tumour burden FL. Substantial delay in TTNT with early rituximab makes it an excellent option for patients seeking to defer/avoid chemotherapy. #lymsm
Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial
These mature data with 15 years of follow-up confirm that early rituximab monotherapy substantially delays the need for new treatment for patients with advanced stage, asymptomatic low tumour burden f...
www.thelancet.com
April 28, 2025 at 11:07 PM
Reposted by Dr Michael Hadjihari
5million MORE General Practice appointments per month compared to 2019 (30million / half the population)

A&E is struggling but 2million attendances a month has barely increased

No one is listening!
General Practices are breaking

#GeneralPractice #MedSky
November 19, 2024 at 9:24 PM